Loading...
Thumbnail Image
Publication

Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine

Martinez-Becerra, Francisco J.
Chen, Xiaotong
Dickenson, Nicholas E.
Choudhari, Shyamal P.
Harrison, Kelly
Clements, John D.
Picking, William D.
Van De Verg, Lillian L.
Walker, Richard I.
Picking, Wendy Lynn
Citations
Altmetric:
Abstract
Shigellosis is an important disease in the developing world, where about 90 million people become infected with Shigella spp. each year. We previously demonstrated that the type three secretion apparatus (T3SA) proteins IpaB and IpaD are protective antigens in the mouse lethal pulmonary model. In order to simplify vaccine formulation and process development, we have evaluated a vaccine design that incorporates both of these previously tested Shigella antigens into a single polypeptide chain. To determine if this fusion protein (DB fusion) retains the antigenic and protective capacities of IpaB and IpaD, we immunized mice with the DB fusion and compared the immune response to that elicited by the IpaB/IpaD combination vaccine. Purification of the DB fusion required coexpression with IpgC, the IpaB chaperone, and after purification it maintained the highly α-helical characteristics of IpaB and IpaD. The DB fusion also induced comparable immune responses and retained the ability to protect mice against Shigella flexneri and S. sonnei in the lethal pulmonary challenge. It also offered limited protection against S. dysenteriae challenge. Our results show the feasibility of generating a protective Shigella vaccine comprised of the DB fusion.
Description
Date
2013-12
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Martinez-Becerra, F. J., Chen, X., Dickenson, N. E., Choudhari, S. P., Harrison, K., Clements, J. D., … Picking, W. L. (2013). Characterization of a Novel Fusion Protein from IpaB and IpaD of Shigella spp. and Its Potential as a Pan-Shigella Vaccine. Infection and Immunity, 81(12), 4470–4477. http://doi.org/10.1128/IAI.00859-13
Embedded videos